Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

Norway's wealth fund, the world's largest, has sold all its fixed income investments in Mexican state oil firm Pemex, it said ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

As Stat reports, the federal judge's ruling means patients will lose access to less-expensive versions of Eli Lilly's weight loss drug, as well as diabetes treatment Mounjaro, from compounding ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Lilly is already stocking $550 million in pre-launch inventory to prevent the sort of shortages that plagued its rollout of Mounjaro and Zepbound, Orforglipron complements Mounjaro ...

and Zepbound, which treats obesity. Compound medicine providers were allowed to make and distribute copycat versions of tirzepatide injection products until December 2024, when the FDA issued a ...

Eli Lilly has gone through a similar legal process with tirzepatide, the active ingredient in its weight loss drug Zepbound and diabetes treatment Mounjaro. The FDA declared the U.S. shortage of ...

Pharmaceutical companies like Novo Nordisk and Eli Lilly took the world by storm last year with a new generation of so-called GLP-1 diet products - Ozempic, Wegovy and Zepbound. The drugs were ...

Despite broader market uncertainties, the company’s robust performance in the diabetes and obesity segments, particularly with GLP-1 drugs like Mounjaro and Zepbound, has bolstered analysts ...